Summary
Entropy Neurodynamics Limited (ENP) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Entropy Neurodynamics Limited ever had a stock split?
Entropy Neurodynamics Limited Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jason Alan Carroll CEO | ASX Exchange | AU0000433583 ISIN |
| US Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Tryptamine Therapeutics Limited is a clinical-stage pharmaceutical development company with operations predominantly in Canada and the United States, though it is based in Camberwell, Australia. The core focus of the company lies in the development of psilocybin-related molecules, tapping into the therapeutic potential of these substances for various disorders. By leveraging cutting-edge science and clinical research, Tryptamine Therapeutics aims to pioneer a new era in the treatment of conditions such as binge eating disorder, fibromyalgia, and chronic pain, amongst others. Their innovative approaches signify a novel stride forward in psychopharmacology, potentially offering new hope to patients with conditions inadequately managed by current treatment modalities.
Products and Services
- TRP-8803
This proprietary formulation of IV-infused psilocin has successfully completed a Phase 2a clinical trial. It is primarily being developed for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. TRP-8803 represents a significant advancement in the therapeutic use of psilocybin-related molecules, offering a potentially innovative treatment option for patients suffering from these complex conditions. The IV infusion method of TRP-8803 allows for controlled dosing and the possibility of a more predictable pharmacokinetic profile, which could be beneficial in a clinical setting.
- TRP-8802
TRP-8802 is a synthetic and oral form of psilocybin, designed as a treatment option for binge eating, chronic pain, and other indications. Its development underscores the company’s commitment to diversifying therapeutic modalities under the umbrella of psychedelic medicine. Oral psilocybin, like TRP-8802, offers ease of administration and the potential for wider therapeutic applications, making it an important component of Tryptamine Therapeutics Limited’s product pipeline. The use of synthetic psilocybin ensures consistency in dosage and quality, critical aspects for clinical research and eventual therapeutic use.
